# Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

> **NCT00533273** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Advanced Dupuytren's Disease

## Interventions

- **BIOLOGICAL:** collagenase clostridium histolyticum

## Key facts

- **NCT ID:** NCT00533273
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533273, "Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00533273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*